138 related articles for article (PubMed ID: 25659215)
1. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
Koh C; Heller T
Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
[No Abstract] [Full Text] [Related]
2. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
Maraolo AE; Minervini F; Tosone G
Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
[No Abstract] [Full Text] [Related]
3. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
Ouzan D; Pénaranda G; Joly H; Halfon P
J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
[No Abstract] [Full Text] [Related]
4. Long-term therapy of chronic delta hepatitis with peginterferon alfa.
Heller T; Rotman Y; Koh C; Clark S; Haynes-Williams V; Chang R; McBurney R; Schmid P; Albrecht J; Kleiner DE; Ghany MG; Liang TJ; Hoofnagle JH
Aliment Pharmacol Ther; 2014 Jul; 40(1):93-104. PubMed ID: 24815494
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of chronic hepatitis D with a short course of peginterferon alfa-2a.
Ferenci P; Formann E; Romeo R
Am J Gastroenterol; 2005 Jul; 100(7):1626-7. PubMed ID: 15985000
[No Abstract] [Full Text] [Related]
6. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
7. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
Scholtès C; Kumar R; Zoulim F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
[No Abstract] [Full Text] [Related]
8. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon therapy of chronic hepatitis D: in need of revision.
Rizzetto M; Smedile A
Hepatology; 2015 Apr; 61(4):1109-11. PubMed ID: 25348580
[No Abstract] [Full Text] [Related]
10. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
11. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta.
Heidrich B; Yurdaydın C; Kabaçam G; Ratsch BA; Zachou K; Bremer B; Dalekos GN; Erhardt A; Tabak F; Yalcin K; Gürel S; Zeuzem S; Cornberg M; Bock CT; Manns MP; Wedemeyer H;
Hepatology; 2014 Jul; 60(1):87-97. PubMed ID: 24585488
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
13. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
Moucari R
J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
[No Abstract] [Full Text] [Related]
15. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
16. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
17. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
18. Quantitative hepatitis B surface antigen combined with hepatitis B e antigen as sustained virological response predictors during extended therapy with Peginterferon alfa-2a for hepatitis B e antigen-positive chronic hepatitis B.
Chen J; Zhang DH; Xu CR; Zhu MY; Yang ZT; Gong QM; Yu DM; Zhang XX
J Clin Virol; 2015 Nov; 72():88-94. PubMed ID: 26476325
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir.
Chen GY; Su TH; Kao JH
J Formos Med Assoc; 2015 Nov; 114(11):1140-1. PubMed ID: 23791143
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
